Previous studies have implied that a variety of cyclins and CDKs, such as CDK4, cyclin B1, Cdc2, and p16, are enhanced in the brains of AD patients (McShea et al., 1997; Vincent et al., 1997; Busser et al., 1998). This evidence concerns the gene CCNB1 and Alzheimer disease.